The WACC of Translate Bio Inc (TBIO) is 10.5%.
Range | Selected | |
Cost of equity | 11.60% - 23.30% | 17.45% |
Tax rate | -% - -% | -% |
Cost of debt | 7.00% - 11.80% | 9.40% |
WACC | 7.6% - 13.4% | 10.5% |
Category | Low | High |
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 4.6% | 5.6% |
Adjusted beta | 1.68 | 3.29 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 11.60% | 23.30% |
Tax rate | -% | -% |
Debt/Equity ratio | 6.35 | 6.35 |
Cost of debt | 7.00% | 11.80% |
After-tax WACC | 7.6% | 13.4% |
Selected WACC | 10.5% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for TBIO:
cost_of_equity (17.45%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (1.68) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.